Dr. Priyom Bose

Feature Writer

B.Sc. Botany, M.Sc. Plant Biology and Biotechnology, Ph.D. Plant Biology and Biotechnology

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Articles from Priyom

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Now, a new study posted to the bioRxiv* preprint server focuses on functional immune memory to SARS-CoV-2, up to nine months in a Southeast Asian cohort, in the absence of re-infection.

16 Aug 2021

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, which has claimed more than 4.3 million lives worldwide. Even after implementing various measures, such as vaccination and social restrictions, SARS-CoV-2 and its variants of concern (VoC) leave the world's public health systems and economies in turmoil.

16 Aug 2021

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

The safety, immunogenicity, and efficacy of the vaccines in adolescents are largely unknown. Now, a new study published in the New England Journal of Medicine evaluates the safety and efficacy of the mRNA-1273 vaccine in adolescents (12-17 years of age).

16 Aug 2021

SARS-CoV-2 Spike may trigger production of antibodies that cross-react with human thrombopoietin to induce thrombocytopenia

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected individuals often suffer from thrombocytopenia, a condition associated with low platelet counts. The cytokine thrombopoietin regulates platelet count. Previous studies have reported that thrombocytopenia can increase the coronavirus disease 2019 (COVID-19) mortality rate by about five times.

16 Aug 2021

Research suggests toll-like receptor 4 appears to play role in severe COVID

A group of researchers re-evaluated their previously proposed hypothesis, which stated that the TLR4 activated by the spike glycoprotein S1 domain increases ACE2 expression and, thereby, aids in COVID-19 infection.

16 Aug 2021

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

A new study published in the journal Nature Communications has reported two neutralizing antibodies, namely, nCoVmab1 and nCoVmab2, which are potent against SARS-CoV-2.

13 Aug 2021

How replication and recombination contribute to emergence of SARS-CoV-2 variants

The coronavirus disease 2019 (COVID-19) pandemic has been caused by the rapid outbreak of a novel coronavirus, namely, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). SARS-CoV-2 was first reported in late December 2019 in Wuhan, China. Since then, the virus has already claimed more than 4.3 million lives worldwide.

13 Aug 2021

Researchers quantify left-over COVID vaccine in used Pfizer-BioNTech vials

A new observational study, published on medRxiv* preprint server, has evaluated the unused residual Pfizer-BioNTech vaccine in vials. Bainbridge Prepares (BP), an organization consisting of community medical and non-medical volunteers, supported the research.

11 Aug 2021

Norwegian study on the benefits of COVID vaccination for residents and employees in nursing homes

It is important to understand the vaccine effectiveness (VE) to determine how much protection it offers to the general population. Unfortunately, only a few studies are available that have determined the effect of the COVID-19 vaccine among the residents of LTCFs.

11 Aug 2021

New estimate of total immunity to SARS-CoV-2 in Texas

According to researchers in Texas, a lack of appropriate testing in the US has led to an underestimation of seroprevalence in the U.S., thus making it difficult to estimate population immunity to SARS-CoV-2 or vaccination.

10 Aug 2021

Dr. Priyom Bose

Articles from Priyom

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Moderna COVID-19 vaccine safe and efficacious in adolescents according to a new study

SARS-CoV-2 Spike may trigger production of antibodies that cross-react with human thrombopoietin to induce thrombocytopenia

Research suggests toll-like receptor 4 appears to play role in severe COVID

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

How replication and recombination contribute to emergence of SARS-CoV-2 variants

Researchers quantify left-over COVID vaccine in used Pfizer-BioNTech vials

Norwegian study on the benefits of COVID vaccination for residents and employees in nursing homes

New estimate of total immunity to SARS-CoV-2 in Texas

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News